BridgeBio Pharma, Inc.

Aug 14, 2026

●Equity OfferingCorporate

Pricing of secondary offering of 5,000,000 shares by KKR Genetic Disorder L.P.

Aug 13, 2026

▼Equity OfferingCorporate

Launch of secondary public offering of 5,000,000 shares by KKR Genetic Disorder L.P.

Jun 29, 2026

◆Oral PresentationInfigratinibApprovedPresentation

Oral presentation on health-related quality of life from PROPEL study at ICCBH 2026

achondroplasiasource ↗

Jun 29, 2026

◆Poster PresentationPresentation

Poster on ACCEL observational study in hypochondroplasia at ICCBH 2026

hypochondroplasiasource ↗

Jun 28, 2026

◆Late-BreakerInfigratinibApprovedPresentation

Late-breaking oral presentation of additional positive data from PROPEL 3 at ICCBH 2026

achondroplasiasource ↗

Jun 28, 2026

◆Poster PresentationInfigratinibApprovedPresentation

Poster on design of PROPEL Infant and Toddler study at ICCBH 2026

achondroplasiasource ↗

May 27, 2026

▲FDA Filing AcceptedBBP-418FiledRegulatory Filing

FDA accepted NDA for BBP-418 with Priority Review

LGMD2I/R9source ↗

May 27, 2026

▲AdCom CancelledBBP-418FiledAdvisory Committee

FDA not planning to hold advisory committee meeting

LGMD2I/R9source ↗

May 27, 2026

▲Priority ReviewBBP-418FiledRegulatory Filing

Priority Review granted for BBP-418 NDA

LGMD2I/R9source ↗

May 12, 2026

◆Oral PresentationEncaleretFiledPresentation

Primary results from Phase 3 CALIBRATE trial of encaleret in ADH1 presented at 2026 ECE

autosomal dominant hypocalcemia type 1 (ADH1)source ↗

May 12, 2026

●NDA SubmissionEncaleretFiledRegulatory Filing

NDA submission to FDA for encaleret in ADH1

autosomal dominant hypocalcemia type 1 (ADH1)source ↗

~May 2026

▲Oral PresentationAcoramidisApprovedPresentation

Acoramidis reduces sTTR variability and outpatient worsening heart failure at Heart Failure 2026

transthyretin amyloid cardiomyopathy (ATTR-CM)source ↗

May 11, 2026

▲Poster PresentationAcoramidisApprovedPresentation

Effect of acoramidis on improvement or maintenance of health status at Heart Failure 2026

transthyretin amyloid cardiomyopathy (ATTR-CM)source ↗

May 10, 2026

◆Poster PresentationPresentation

Baseline quality of life measures in CLARIFY disease monitoring study presented at 2026 ECE

autosomal dominant hypocalcemia type 1 and type 2source ↗

May 7, 2026

●Quarterly UpdateCorporate

Q1 2026 financial results reported

May 6, 2026

▲Equity OfferingCorporate

Board approved $500 million stock repurchase program

Apr 28, 2026

●Quarterly UpdateCorporate

BridgeBio launches national health education campaign 'Don't Pass On Your Heart Health' featuring Morgan Freeman and Howard H. White

Mar 30, 2026

◆Late-BreakerAcoramidisApprovedPresentation

Long-Term Survival Benefits and Disease Stabilization with Acoramidis in Patients with ATTR-CM

ATTR-CMsource ↗

Mar 30, 2026

●NDA SubmissionBBP-418FiledRegulatory Filing

NDA submission to FDA for BBP-418

LGMD2I/R9source ↗

Mar 11, 2026

◆Late-BreakerBBP-418FiledPresentation

Late-breaking oral presentation of additional data from interim analysis of FORTIFY trial

limb-girdle muscular dystrophy type 2I/R9 (LGMD2I/R9)source ↗

Mar 10, 2026

◆Poster PresentationBBP-418FiledPresentation

Poster: The Journey of BBP-418: From LGMD2I/R9 Disease Pathophysiology to Registrational Clinical Trials

limb-girdle muscular dystrophy type 2I/R9 (LGMD2I/R9)source ↗

Mar 2026

▲Oral PresentationBBP-418FiledPresentation

Late-breaking oral presentation at 2026 MDA Clinical and Scientific Conference

LGMD2I/R9source ↗

Feb 24, 2026

●Quarterly UpdateCorporate

Q4 and full year 2025 financial results reported

Unlock the full BBIO catalyst timeline

Every PDUFA date, readout, approval and corporate move, tiered by market impact and updated daily.

Institutional-grade data · Cancel anytime

Past FDA Catalysts and PDUFA Decisions

How BBIO actually traded into and out of each decision

Date	Drug	Catalyst	Stage	Reaction	Event Move %	Best Trade %
2026-10-11	encaleret	Phase 3 data presentation	Phase 3

Unlock 13 more BBIO historical catalysts

Institutional-grade data · Cancel anytime

Reaction: 30 trading days around the event · Event Move: close to close on decision day · Best Trade: peak run-up from entry 10 days before the decision

Drug Pipeline Intelligence

Pipeline Score

Pipeline Value

Commercial Value

Valuation Signal

Drugs Scored

rNPV / MCap

Top Drug

Top 12%

Mid Cap

(rank 80 of 657)

Percentile Rank

Commercial products (revenue basis: trailing 4 quarters of total revenue (10-K and 10-Q), to Jun 2026; product lines: last four quarters to Jun 2026 (10-K and 10-Q))

Product	Revenue	Prior period	Change
Attruby	•••	•••	•••

Drug	Indication	Phase	Status	Enroll	Est. Completion
BBP-418 Small moleculeNCT04800874	LGMD2I	NDA/BLA	ACTIVE NOT_RECRUITING	14	Nov 1, 2026
BBP-418 Small moleculeNCT05775848	Limb-Girdle Muscular Dystrophy Type 2I (LGMD2I)	NDA/BLA	ACTIVE NOT_RECRUITING	188	Jul 1, 2027
Infigratinib Small moleculeNCT07393373	Hypochondroplasia	Phase 2	ENROLLING BY_INVITATION	159	May 31, 2036
BBP-631 Gene therapyNCT04783181	Congenital Adrenal Hyperplasia	Phase 1	ACTIVE NOT_RECRUITING	8	Feb 1, 2029
BBP-812 Gene therapyNCT04998396	Canavan Disease	Phase 1	RECRUITING	26	Oct 8, 2032
Encaleret Small moleculeNCT07805356	Hypoparathyroidism	Phase 3	RECRUITING	160	Jan 1, 2033
Acoramidis Small moleculeMarketedNCT07116473	Amyloidosis in Transthyretin (TTR)	Phase 3	NOT YET_RECRUITING	250	Dec 1, 2037
Acoramidis Small moleculeMarketedNCT04988386	Amyloid Cardiomyopathy, Transthyretin-Related	Phase 3	ACTIVE NOT_RECRUITING	445	May 15, 2028
Encaleret Small moleculeNCT05680818	Autosomal Dominant Hypocalcemia (ADH)	NDA/BLA	ACTIVE NOT_RECRUITING	80	Aug 1, 2029
Encaleret Small moleculeNCT07080385	Autosomal Dominant Hypocalcemia Type 1 (ADH1)	NDA/BLA	RECRUITING	28	Dec 1, 2030
Infigratinib Small moleculeNCT04265651	Achondroplasia	NDA/BLA	COMPLETED	575	Oct 21, 2024
BBP-711 Small moleculeCompletedNCT04876924	Undisclosed	Phase 1	COMPLETED	92	Feb 27, 2022
PORT-77 Small moleculeNCT06971900	Erythropoietic Protoporphyria (EPP)	Phase 2	COMPLETED	253	Nov 24, 2025
ORGN001 Small moleculeCompletedNCT02047461	Molybdenum Cofactor Deficiency, Type A	Phase 2	COMPLETED	13	Oct 1, 2022
PTR-01 Small moleculeCompletedNCT03752905	Recessive Dystrophic Epidermolysis Bullosa	Phase 2	COMPLETED	20	Nov 30, 2020
Acoramidis Small moleculeMarketedNCT04769479	Amyloidosis	Phase 3	COMPLETED	1,233	Sep 3, 2021
Acoramidis Small moleculeMarketedNCT03458130	Familial ATTR-CM (ATTRm-CM, or FAC)	Phase 2	COMPLETED	49	Oct 5, 2018
ALXN1101 Small moleculeMarketedNCT01894165	Molybdenum Cofactor Deficiency (MoCD)	Phase 1	COMPLETED	24	Sep 1, 2013

Unlock the BBIO pipeline intelligence model

PTRS, rNPV, enrollment velocity, trial design quality and ML risk signals for every asset above.

Institutional-grade data · Cancel anytime

Clinical Trial Results

Readouts, endpoints and source filings for every BBIO program

Drug Name	Indication	Phase	Date	Trial Results Summary	Title	Source
Acoramidis	ATTR-CM		2026-10-11	18% lower risk of a composite of death, all-cause hospitalization, new-onset atrial fibrillation, and diuretic intensification versus tafamidis (HR 0.82; 95% CI 0.73-0.93; p<0.01); 27% lower risk of cardiovascular hospitalization; 27% lower risk of heart failure hospitalization; 25% lower risk of all-cause hospitalization; 34% reduction in clinical worsening events versus tafamidis (p=0.046)Read More	Acoramidis Associated with Significantly Improved Clinical Outcomes Versus Tafamidis in ATTR-CM in an Independent, Real-World Study of U.S. Electronic Health RecordsRead More

Scroll for more · summaries link to the source press release

Unlock every BBIO trial readout

Institutional-grade data · Cancel anytime

Inside Trades

Unlock BBIO insider buying and selling

Monthly insider buys and sells against the stock price, with the insider sentiment reading.

Institutional-grade data · Cancel anytime

Insider	Side	Shares	Price	Value	Date
Kumar NeilDirector, Officer (Chief Executive Officer)	Sell	-8,721 496,965 held	$69.01		09/17/2026

Unlock the full BBIO insider trade log

Institutional-grade data · Cancel anytime

Hedge Fund 13F Activity

Hedge Funds invested in BBIO

Fund	% of Portfolio	Current MV	Shares Owned	Activity
Frazier Life Sciences Management, L.P.	2.5 % (-62.1 %)	115.31 M	1.55 M	-55.1% ( -1.90 M)

Unlock every fund holding BBIO

Every 13F position with quarter over quarter share flow and average entry price.

Institutional-grade data · Cancel anytime

BBIO Institutional Ownership Trends

BBIO Short Interest

Shares sold short, counted twice a month.

11.42%

Short % of Float

of tradable shares sold short

20.0M

Shares Sold Short

+1.7% vs prior count

7.7 High

Days to Cover

trading days of normal volume to buy every short share back

2.6M

Avg Daily Volume

the average used for days to cover

Unlock BBIO short interest history

Two years of days to cover and shares sold short, with every count and its change.

Institutional-grade data · Cancel anytime

Options Data

Open Interest

Call OI

Put OI

Put-Call Ratio

OI 30-day avg

Today vs avg

Option Volume

Call Vol

Put Vol

Put-Call Ratio

Vol 30-day avg

Today vs avg

Option Chain Statistics

Expiry	Call Vol	Put Vol	Vol P/C	Call OI	Put OI	OI P/C	IV Call	IV Call OI-Wtd	IV Call Vol-Wtd	IV Put	IV Put OI-Wtd	IV Put Vol-Wtd
2026-11-20

Unlock BBIO option chain statistics

Per-expiry call and put volume, open interest, put-call ratios and implied volatility.

Institutional-grade data · Cancel anytime

Real-Time Option Chain

Calls			Strike	Puts
Last	Vol	OI	Strike	Last	Vol	OI
No data available

Unlock the live BBIO option chain

Live calls and puts by strike: last price, volume and open interest for every expiry.

Institutional-grade data · Cancel anytime

Calls vs Puts by Expiry

CallsPutsLog scale

Unlock BBIO options analytics

Institutional-grade data · Cancel anytime

Competitive positioning

How BBIO ranks across every disease it competes in

Competitive Position is a premium feature

See how BBIO ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.

Start free trial

BBIO News

BridgeBio Reports Third Quarter 2026 Financial Results and Corporate Updates

BridgeBio reported $353.2 million in Q3 2026 revenues, driven by Attruby's growth. The company highlighted positive real-world evidence for acoramidis compared to tafamidis. Upcoming PDUFA dates for BBP-418, infigratinib, and encaleret signal potential advancements in treatment options. BridgeBio's cash reserves of $1.5 billion support ongoing and future product launches.

Oct 22, 2026

BridgeBio to Report Third Quarter 2026 Financial Results and Commercial Updates on October 29, 2026 at 4:30 pm ET

BridgeBio Pharma, Inc. will release its third quarter 2026 financial results on October 29, 2026. The company will host a conference call at 4:30 pm ET to discuss these results and provide updates on its programs. A live webcast will be available for interested participants.

Oct 16, 2026

BridgeBio Pharma Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

BridgeBio Pharma has announced the approval of equity grants to 32 new employees, totaling 57,853 shares of common stock. These grants are part of an inducement for new hires in accordance with Nasdaq Listing Rule 5635(c)(4). The shares will vest over time, contingent on continued employment. This initiative reflects BridgeBio's commitment to expanding its workforce to support its mission in developing treatments for genetic conditions.

Oct 11, 2026

Acoramidis Associated with Significantly Improved Clinical Outcomes Versus Tafamidis in ATTR-CM in an Independent, Real-World Study of U.S. Electronic Health Records

Acoramidis demonstrated significantly improved clinical outcomes compared to tafamidis in patients with ATTR-CM, according to a real-world study utilizing U.S. electronic health records. The analysis revealed an 18% lower risk of adverse events, including hospitalization and mortality. These results support the use of acoramidis as a preferred treatment option for patients with this condition.

Oct 11, 2026

Encaleret Increased Bone Turnover and Improved Participant-Reported Symptoms in the Phase 3 CALIBRATE Trial in ADH1

BridgeBio Pharma's Phase 3 CALIBRATE trial showed that encaleret significantly improved bone turnover and participant-reported symptoms in patients with autosomal dominant hypocalcemia type 1 (ADH1). The FDA has accepted the New Drug Application for encaleret and granted it Priority Review, with a target action date set for May 8, 2027. Additionally, the first participant has been dosed in the RECLAIM-HP trial for chronic hypoparathyroidism.

Oct 6, 2026

BridgeBio to Present New Acoramidis Data, Including Independent Comparative Real-World EHR Data at the HFSA Annual Scientific Meeting 2026

BridgeBio Pharma will present new data on acoramidis at the HFSA Annual Scientific Meeting 2026. The presentations will include one oral presentation, three rapid-fire oral presentations, and six poster presentations focused on the treatment of transthyretin amyloid cardiomyopathy (ATTR-CM). Acoramidis is highlighted as a first-line treatment option, with data supporting its clinical profile and effectiveness.

Oct 6, 2026

BridgeBio to Present Additional Evidence from the Phase 3 CALIBRATE Trial of Encaleret in ADH1 at the ASBMR 2026 Annual Meeting

BridgeBio Pharma will present additional findings from the Phase 3 CALIBRATE trial of encaleret for autosomal dominant hypocalcemia type 1 (ADH1) at the ASBMR 2026 Annual Meeting. The presentations will include patient-reported outcomes and bone turnover effects. Additionally, data on genetic testing initiatives and safety profiles in children with achondroplasia will be shared.

Oct 6, 2026

BBIOFDA Updates

BridgeBio Announces FDA Acceptance and Priority Review of NDA for Oral Infigratinib for Children with Achondroplasia

BridgeBio announced that the FDA has accepted its New Drug Application for oral infigratinib, a potential first oral treatment for children with achondroplasia, with a target action date of February 4, 2027. The PROPEL 3 trial demonstrated significant efficacy, including the largest annualized height velocity reported in a Phase 3 study. The company is prepared for a U.S. launch upon approval and plans to submit a Marketing Authorization Application to the EMA.

Oct 5, 2026

BridgeBio and Community Partners Launch Nationwide ATTR-CM Education Effort Ahead of World Amyloidosis Day

BridgeBio Pharma has launched a nationwide education initiative to raise awareness about transthyretin amyloid cardiomyopathy (ATTR-CM), particularly among Black Americans who are at higher risk. The campaign kicks off with a YouTube premiere on October 6, featuring discussions led by notable figures in health and culture. The initiative aims to improve recognition and understanding of ATTR-CM, which is often misdiagnosed or overlooked.

Oct 5, 2026

BBP-418 Demonstrates Potential to Be Disease Modifying Therapy, Restoring Cardiac and Disease Markers to Unaffected Levels

BridgeBio Pharma presented promising data on BBP-418 during the Phase 3 FORTIFY trial for LGMD2I/R9. At the 12-month interim analysis, 100% of treated individuals normalized HS troponin I levels, and 54% showed stable or improved left ventricular ejection fraction (LVEF). BBP-418 is under FDA Priority Review with a target action date of November 27, 2026, and may become the first approved therapy for this condition.

Acoramidis Demonstrates Real-World Benefit Versus Tafamidis in ATTR-CM, Reducing Risk of Clinical Worsening

Acoramidis has demonstrated a statistically significant benefit over tafamidis in reducing clinical worsening events in patients with ATTR-CM, according to a recent study. The findings indicate a 34% reduction in composite clinical worsening events and a 43% reduction in diuretic intensification. These results highlight acoramidis's potential as a frontline treatment option. Further studies are planned to validate these findings.

Sep 9, 2026

Oral Infigratinib Shows Meaningful Benefits Beyond Growth Within 52 Weeks in Children with Achondroplasia in the Phase 3 PROPEL 3 Trial

The Phase 3 PROPEL 3 trial of oral infigratinib demonstrated meaningful benefits for children with achondroplasia, including stabilization of sleep apnea and reduced ear infections. The treatment showed sustained improvements in growth and body proportionality over three years, with a favorable safety profile. BridgeBio has submitted an NDA to the FDA, anticipating a U.S. launch in mid-2027.

Sep 2, 2026

BridgeBio to Present New Data on the Impact of Oral Infigratinib on Medical Complications in Achondroplasia at the Annual ESPE Meeting 2026

BridgeBio Pharma will present new findings on oral infigratinib's effects on achondroplasia at the Annual ESPE Meeting 2026. The late-breaking oral presentation will focus on the results from the PROPEL 3 study, alongside additional posters detailing longer-term data. This research aims to address critical medical complications associated with achondroplasia and hypochondroplasia.

Sep 1, 2026

BridgeBio to Participate in September Investor Conferences

BridgeBio Pharma, Inc. announced its participation in several upcoming healthcare investor conferences in September 2026. The management team will engage in fireside chats at notable events, including the Wells Fargo Healthcare Conference and the Morgan Stanley Global Healthcare Conference. Live webcasts of these presentations will be accessible on the company's website.

Aug 31, 2026

BridgeBio Announces Agreement with U.S. Government to Improve Affordability and Access to Critical Medicines for Americans

BridgeBio Pharma has entered a voluntary agreement with the U.S. government to enhance access to its medicines and reduce costs for American patients, particularly those on Medicaid. The agreement aims to maintain innovation in rare disease treatments while ensuring affordability. BridgeBio's Attruby will remain available through Medicare without future pricing mandates, and the company continues to support patients through its ForgingBridges program.

Aug 30, 2026

Acoramidis Demonstrates Reversal of Cardiac Structural Disease Progression and Functional Decline and Significantly Increases Days Alive and Free from Hospitalization in ATTR-CM

Acoramidis, a treatment for transthyretin amyloid cardiomyopathy (ATTR-CM), has shown promising results in reversing cardiac disease progression and improving patient outcomes. In a Phase 3 study, patients treated with acoramidis experienced significant increases in days alive and free from hospitalization. The therapy demonstrated long-term efficacy and safety across different genetic subgroups, marking a potential shift in treatment for ATTR-CM.

Aug 26, 2026

BridgeBio Announces First Participant Dosed in ASCEND-ATTR, a Phase 3b/4 Study Evaluating the Long-Term Effects of Acoramidis on Disease Regression in ATTR-CM

BridgeBio Pharma has initiated the ASCEND-ATTR study, dosing its first participant to evaluate the long-term effects of acoramidis on cardiac structure and function in patients with ATTR-CM. This Phase 3b/4 study aims to determine if acoramidis can lead to sustained improvements in cardiac health, building on previous positive findings from the ATTRibute-CM CMR substudy. The study will enroll approximately 150 participants and utilize advanced imaging techniques to assess treatment efficacy over 36 months.

Aug 24, 2026

BridgeBio to Present New Acoramidis Data from Open-Label Extension Analyses in ATTR-CM at ESC Congress 2026

BridgeBio Pharma will present new data on acoramidis for ATTR-CM at the ESC Congress 2026. The findings highlight acoramidis as a first-line treatment, demonstrating significant clinical benefits. Presentations include results on survival benefits and quality of life improvements, further establishing the drug's efficacy in managing this condition.

Aug 14, 2026